Core Insights - TuHURA Biosciences, Inc. is focused on developing novel technologies to address resistance to cancer immunotherapy, with a particular emphasis on its Phase 3 programs and innovative antibody drug conjugates [4][5][6] Group 1: Company Overview - TuHURA is a Phase 3 immune-oncology company that aims to overcome both primary and acquired resistance to cancer immunotherapy, which are common reasons for treatment failure [4] - The company is preparing to initiate a randomized placebo-controlled Phase 3 trial of its lead product, IFx-2.0, in combination with Keytruda® for advanced Merkel Cell Carcinoma [5] - TuHURA's acquisition of Kineta, Inc. is expected to enhance its portfolio, including the rights to Kineta's KVA12123 antibody, with the merger targeted to close in Q2 2025 [3] Group 2: Upcoming Events - James A. Bianco, M.D., CEO of TuHURA, will present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, highlighting the company's Phase 3 program and its bi-specific immune modulating antibody drug [1][2] - Management will also be available for one-on-one meetings with qualified investors during the conference [2] Group 3: Research and Development - TuHURA is leveraging its Delta Opioid Receptor technology to develop bi-specific immune modulating antibody drug conjugates targeting Myeloid Derived Suppressor Cells, aiming to prevent T cell exhaustion [7] - The company plans to initiate a randomized trial in Q3 2025 for a menin inhibitor combined with a VISTA inhibiting antibody in relapsed or refractory Acute Myeloid Leukemia (AML) [6]
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference